Cargando…

Olanzapine Poisoning in Patients Treated at the National Poison Control Centre in Belgrade, Serbia in 2017 and 2018: A Brief Review of Serum Concentrations and Clinical Symptoms

Olanzapine is a thienobenzodiazepine class antipsychotic that strongly antagonises the 5-HT2A serotonin receptor, but acute poisonings are reported rarely. Symptoms of an overdose include disorder of consciousness, hypersalivation, myosis, and coma. Serum concentration higher than 0.1 mg/L is toxic,...

Descripción completa

Detalles Bibliográficos
Autores principales: Đorđević, Snežana, Vukčević, Nataša Perković, Antunović, Marko, Kilibarda, Vesna, Ercegović, Gordana Vuković, Stošić, Jasmina Jović, Vučinić, Slavica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287839/
https://www.ncbi.nlm.nih.gov/pubmed/35792773
http://dx.doi.org/10.2478/aiht-2022-73-3635
_version_ 1784748336985669632
author Đorđević, Snežana
Vukčević, Nataša Perković
Antunović, Marko
Kilibarda, Vesna
Ercegović, Gordana Vuković
Stošić, Jasmina Jović
Vučinić, Slavica
author_facet Đorđević, Snežana
Vukčević, Nataša Perković
Antunović, Marko
Kilibarda, Vesna
Ercegović, Gordana Vuković
Stošić, Jasmina Jović
Vučinić, Slavica
author_sort Đorđević, Snežana
collection PubMed
description Olanzapine is a thienobenzodiazepine class antipsychotic that strongly antagonises the 5-HT2A serotonin receptor, but acute poisonings are reported rarely. Symptoms of an overdose include disorder of consciousness, hypersalivation, myosis, and coma. Serum concentration higher than 0.1 mg/L is toxic, while concentration above 1 mg/L can be fatal. Here we report key data about 61 patients admitted to the National Poison Control Centre in Belgrade, Serbia over olanzapine poisoning in 2017 and 2018. The ingested doses ranged from 35 to 1680 mg, and time from ingestion to determination from two to 24 hours. In 34 patients olanzapine serum concentrations were in the therapeutic range and in 27 in the toxic range. In five patients they were higher than fatal, but only one patient died. The most common symptoms of poisoning were depressed consciousness (fluctuating from somnolence to coma), tachycardia, hypersalivation, hypotension, myosis, and high creatine kinase. All patients but one recovered fully after nonspecific detoxification and symptomatic and supportive therapy.
format Online
Article
Text
id pubmed-9287839
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Sciendo
record_format MEDLINE/PubMed
spelling pubmed-92878392022-07-27 Olanzapine Poisoning in Patients Treated at the National Poison Control Centre in Belgrade, Serbia in 2017 and 2018: A Brief Review of Serum Concentrations and Clinical Symptoms Đorđević, Snežana Vukčević, Nataša Perković Antunović, Marko Kilibarda, Vesna Ercegović, Gordana Vuković Stošić, Jasmina Jović Vučinić, Slavica Arh Hig Rada Toksikol Original Article Olanzapine is a thienobenzodiazepine class antipsychotic that strongly antagonises the 5-HT2A serotonin receptor, but acute poisonings are reported rarely. Symptoms of an overdose include disorder of consciousness, hypersalivation, myosis, and coma. Serum concentration higher than 0.1 mg/L is toxic, while concentration above 1 mg/L can be fatal. Here we report key data about 61 patients admitted to the National Poison Control Centre in Belgrade, Serbia over olanzapine poisoning in 2017 and 2018. The ingested doses ranged from 35 to 1680 mg, and time from ingestion to determination from two to 24 hours. In 34 patients olanzapine serum concentrations were in the therapeutic range and in 27 in the toxic range. In five patients they were higher than fatal, but only one patient died. The most common symptoms of poisoning were depressed consciousness (fluctuating from somnolence to coma), tachycardia, hypersalivation, hypotension, myosis, and high creatine kinase. All patients but one recovered fully after nonspecific detoxification and symptomatic and supportive therapy. Sciendo 2022-07-07 /pmc/articles/PMC9287839/ /pubmed/35792773 http://dx.doi.org/10.2478/aiht-2022-73-3635 Text en © 2022 Snežana Đorđević, Nataša Perković Vukčević, Marko Antunović, Vesna Kilibarda, Gordana Vuković Ercegović, Jasmina Jović Stošić, and Slavica Vučinić, published by Sciendo https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
spellingShingle Original Article
Đorđević, Snežana
Vukčević, Nataša Perković
Antunović, Marko
Kilibarda, Vesna
Ercegović, Gordana Vuković
Stošić, Jasmina Jović
Vučinić, Slavica
Olanzapine Poisoning in Patients Treated at the National Poison Control Centre in Belgrade, Serbia in 2017 and 2018: A Brief Review of Serum Concentrations and Clinical Symptoms
title Olanzapine Poisoning in Patients Treated at the National Poison Control Centre in Belgrade, Serbia in 2017 and 2018: A Brief Review of Serum Concentrations and Clinical Symptoms
title_full Olanzapine Poisoning in Patients Treated at the National Poison Control Centre in Belgrade, Serbia in 2017 and 2018: A Brief Review of Serum Concentrations and Clinical Symptoms
title_fullStr Olanzapine Poisoning in Patients Treated at the National Poison Control Centre in Belgrade, Serbia in 2017 and 2018: A Brief Review of Serum Concentrations and Clinical Symptoms
title_full_unstemmed Olanzapine Poisoning in Patients Treated at the National Poison Control Centre in Belgrade, Serbia in 2017 and 2018: A Brief Review of Serum Concentrations and Clinical Symptoms
title_short Olanzapine Poisoning in Patients Treated at the National Poison Control Centre in Belgrade, Serbia in 2017 and 2018: A Brief Review of Serum Concentrations and Clinical Symptoms
title_sort olanzapine poisoning in patients treated at the national poison control centre in belgrade, serbia in 2017 and 2018: a brief review of serum concentrations and clinical symptoms
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287839/
https://www.ncbi.nlm.nih.gov/pubmed/35792773
http://dx.doi.org/10.2478/aiht-2022-73-3635
work_keys_str_mv AT đorđevicsnezana olanzapinepoisoninginpatientstreatedatthenationalpoisoncontrolcentreinbelgradeserbiain2017and2018abriefreviewofserumconcentrationsandclinicalsymptoms
AT vukcevicnatasaperkovic olanzapinepoisoninginpatientstreatedatthenationalpoisoncontrolcentreinbelgradeserbiain2017and2018abriefreviewofserumconcentrationsandclinicalsymptoms
AT antunovicmarko olanzapinepoisoninginpatientstreatedatthenationalpoisoncontrolcentreinbelgradeserbiain2017and2018abriefreviewofserumconcentrationsandclinicalsymptoms
AT kilibardavesna olanzapinepoisoninginpatientstreatedatthenationalpoisoncontrolcentreinbelgradeserbiain2017and2018abriefreviewofserumconcentrationsandclinicalsymptoms
AT ercegovicgordanavukovic olanzapinepoisoninginpatientstreatedatthenationalpoisoncontrolcentreinbelgradeserbiain2017and2018abriefreviewofserumconcentrationsandclinicalsymptoms
AT stosicjasminajovic olanzapinepoisoninginpatientstreatedatthenationalpoisoncontrolcentreinbelgradeserbiain2017and2018abriefreviewofserumconcentrationsandclinicalsymptoms
AT vucinicslavica olanzapinepoisoninginpatientstreatedatthenationalpoisoncontrolcentreinbelgradeserbiain2017and2018abriefreviewofserumconcentrationsandclinicalsymptoms